Filled for bankruptcy in Sep 2023
NOVN - Novan, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Durham,
United States
Type: Equity
NOVN price evolution
NOVN
| (in millions $) | 31 Mar 2023 | 31 Jan 2023 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $13.19 | $13.36 | $15.49 | $37.88 |
| Short term investments | ||||
| Net receivables | $13.84 | $22 | $14.88 | $18.22 |
| Inventory | $1.12 | $1.2 | $1.18 | $1.56 |
| Total current assets | $32.69 | $42.37 | $34.63 | $62.05 |
| Long term investments | $0.58 | $0.58 | ||
| Property, plant & equipment | $15.28 | $15.64 | $15.71 | $16.04 |
| Goodwill & intangible assets | $31.05 | $31.53 | $32.09 | $35.44 |
| Total noncurrent assets | $47.11 | $47.96 | $48.64 | $52.34 |
| Total investments | $0.58 | $0.58 | ||
| Total assets | $79.79 | $90.33 | $83.27 | $114.39 |
| Current liabilities | ||||
| Accounts payable | $14.32 | $13.69 | $4.07 | $6.76 |
| Deferred revenue | $10.02 | $10.66 | $11.31 | $11.96 |
| Short long term debt | $8.39 | $10.49 | $0.25 | $0.23 |
| Total current liabilities | $43.91 | $46.4 | $35.63 | $44.26 |
| Long term debt | $3.39 | $3.74 | $3.8 | $20.2 |
| Total noncurrent liabilities | $38.71 | $39.33 | $40.88 | $57.89 |
| Total debt | $11.77 | $14.23 | $4.05 | $20.43 |
| Total liabilities | $82.62 | $85.72 | $76.51 | $102.14 |
| Shareholders' equity | ||||
| Retained earnings | -$324.4 | -$310.28 | -$307.26 | -$301.23 |
| Other shareholder equity | ||||
| Total shareholder equity | -$2.83 | $4.61 | $6.76 | $12.25 |
| (in millions $) | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $13.36 | $47.67 | $35.88 | $14.25 |
| Short term investments | ||||
| Net receivables | $22 | $4.47 | $4.86 | $0.42 |
| Inventory | $1.2 | |||
| Total current assets | $42.37 | $54.13 | $44.01 | $15.72 |
| Long term investments | $0.58 | |||
| Property, plant & equipment | $15.64 | $13.89 | $2.41 | $12.34 |
| Goodwill & intangible assets | $31.53 | $0.07 | $0.07 | $0.07 |
| Total noncurrent assets | $47.96 | $14.83 | $2.82 | $13.37 |
| Total investments | $0.58 | |||
| Total assets | $90.33 | $68.96 | $46.83 | $29.1 |
| Current liabilities | ||||
| Accounts payable | $13.69 | $2.17 | $1.19 | $1.6 |
| Deferred revenue | $10.66 | $13.25 | $11.23 | $11.5 |
| Short long term debt | $10.49 | $0.48 | $1.16 | |
| Total current liabilities | $46.4 | $11.15 | $8.7 | $12.9 |
| Long term debt | $3.74 | $3.61 | $0.48 | $5.1 |
| Total noncurrent liabilities | $39.33 | $39.49 | $35.15 | $39.98 |
| Total debt | $14.23 | $3.61 | $0.96 | $6.26 |
| Total liabilities | $85.72 | $50.64 | $43.85 | $52.88 |
| Shareholders' equity | ||||
| Retained earnings | -$310.28 | -$278.97 | -$249.28 | -$203.68 |
| Other shareholder equity | -$0.15 | -$0.15 | ||
| Total shareholder equity | $4.61 | $18.32 | $2.98 | -$23.79 |
| (in millions $) | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3.17 | $10.48 | $5.12 | $6.16 |
| Cost of revenue | $1.28 | $3.12 | $1.44 | $2.61 |
| Gross Profit | $1.88 | $7.36 | $3.67 | $3.55 |
| Operating activities | ||||
| Research & development | $4.83 | $3.73 | $4.29 | $3.14 |
| Selling, general & administrative | $10.04 | $6.95 | $8.56 | $8.59 |
| Total operating expenses | $15.35 | $11.16 | $13.29 | $12.29 |
| Operating income | -$13.47 | -$3.8 | -$9.62 | -$8.74 |
| Income from continuing operations | ||||
| EBIT | -$13.79 | -$2.95 | -$5.39 | -$8.27 |
| Income tax expense | $0.06 | |||
| Interest expense | $0.28 | $0.08 | $0.64 | $0.61 |
| Net income | ||||
| Net income | -$14.12 | -$3.02 | -$6.03 | -$8.88 |
| Income (for common shares) | -$14.12 | -$3.02 | -$6.03 | -$8.88 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $23.68 | $2.96 | $4.92 | $4.9 |
| Cost of revenue | $7.38 | |||
| Gross Profit | $16.3 | $2.96 | $4.92 | $4.9 |
| Operating activities | ||||
| Research & development | $15.99 | $20.42 | $19.81 | $25.17 |
| Selling, general & administrative | $34.1 | $12.34 | $11.27 | $10.41 |
| Total operating expenses | $51.69 | $32.87 | $35.13 | $35.58 |
| Operating income | -$35.39 | -$29.91 | -$30.21 | -$30.69 |
| Income from continuing operations | ||||
| EBIT | -$29.86 | -$29.69 | -$29.29 | -$30.64 |
| Income tax expense | ||||
| Interest expense | $1.45 | $0 | ||
| Net income | ||||
| Net income | -$31.31 | -$29.69 | -$29.29 | -$30.64 |
| Income (for common shares) | -$31.31 | -$29.69 | -$29.29 | -$30.64 |
| (in millions $) | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Net income | -$14.12 | -$3.02 | -$6.03 | -$8.88 |
| Operating activities | ||||
| Depreciation | $0.89 | $0.85 | $0.91 | $0.8 |
| Business acquisitions & disposals | -$3.1 | |||
| Stock-based compensation | $0.43 | $0.54 | $0.51 | $0.45 |
| Total cash flows from operations | -$4.25 | -$11.11 | -$9.43 | -$11.11 |
| Investing activities | ||||
| Capital expenditures | -$0.02 | -$1.06 | -$0.41 | -$1.87 |
| Investments | ||||
| Total cash flows from investing | -$0.02 | -$1.06 | -$3 | -$1.87 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $6.47 | $0.33 | $0.03 | $14.99 |
| Net borrowings | -$2.38 | $10.3 | -$10 | |
| Total cash flows from financing | $4.09 | $10.63 | -$9.97 | $14.79 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$0.18 | -$1.54 | -$22.4 | $1.81 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$31.31 | -$29.69 | -$29.29 | -$30.64 |
| Operating activities | ||||
| Depreciation | $2.78 | $0.34 | $1.17 | $2.03 |
| Business acquisitions & disposals | -$15.09 | |||
| Stock-based compensation | $1.88 | $0.28 | $1.31 | $1.84 |
| Total cash flows from operations | -$30.88 | -$24.78 | -$31.06 | -$19.88 |
| Investing activities | ||||
| Capital expenditures | -$4.27 | -$9.05 | -$0.13 | -$0.42 |
| Investments | ||||
| Total cash flows from investing | -$18.86 | -$7.53 | -$0.13 | -$0.42 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $15.92 | $44.46 | $52.06 | $0.82 |
| Net borrowings | $0.3 | $0.96 | ||
| Total cash flows from financing | $16.02 | $44.09 | $52.81 | $25.82 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$33.72 | $11.79 | $21.63 | $5.52 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 28.02M |
| Revenue | $24.92M |
|---|---|
| EBITDA | -$26.95M |
| EBIT | -$30.40M |
| Net Income | -$32.05M |
| Revenue Q/Q | 64.21% |
| Revenue Y/Y | 512.74% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | -0.10 |
| Cash/Share | 0.47 |
| EPS | -$1.14 |
|---|---|
| ROA | -34.86% |
| ROE | -616.76% |
| Debt/Equity | 18.62 |
|---|---|
| Net debt/EBITDA | -2.58 |
| Current ratio | 0.74 |
| Quick ratio | 0.72 |